Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a significant increase in short interest in May. As of May 29th, there was short interest totaling 16,388 shares, an increase of 177.1% from the May 14th total of 5,914 shares. Currently, 0.8% of the company’s shares are short sold. Based on an average daily trading volume, of 8,366 shares, the days-to-cover ratio is presently 2.0 days.

Xenetic Biosciences Trading Up 6.7%

Shares of NASDAQ XBIO traded up $0.20 during midday trading on Friday, reaching $3.20. 46,698 shares of the stock were exchanged, compared to its average volume of 13,293. The company has a market capitalization of $7.33 million, a P/E ratio of -2.67 and a beta of 2.19. Xenetic Biosciences has a 52-week low of $1.90 and a 52-week high of $13.93. The stock has a 50 day moving average price of $3.13 and a 200-day moving average price of $2.67.

Xenetic Biosciences (NASDAQ:XBIO) last released its earnings results on Tuesday, May 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.The company had revenue of $0.81 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Xenetic Biosciences has an average rating of “Sell”.

Institutional Investors Weigh In On Xenetic Biosciences

A hedge fund recently bought a new stake in Xenetic Biosciences stock. DRW Securities LLC bought a new position in Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned about 0.60% of Xenetic Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 15.12% of the company’s stock.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.